The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.